Avalo Therapeutics (AVTX) revenue breakdown
By product, Product revenue, net is the largest at 73% of fiscal 2023 revenue; License and other revenue grew fastest, 73% a year over 3 years.
Revenue by product
Fiscal years, as Avalo Therapeutics reports them in its 10-K filings; fiscal 2023 total $2M.
| Products | 2017 | 2018 | 2019 | 2021 | 2022 | 2023 | Share |
|---|---|---|---|---|---|---|---|
| Product revenue, net | $818,132 | $7M | $7M | $5M | $3M | $1M | 73% |
| License and other revenue | — | — | $100,000 | $625,000 | $15M | $516,000 | 27% |
| License and other revenue | $25M | — | — | — | — | — | — |
| Prescribed dietary supplements | $1M | — | — | — | — | — | — |
| Grant revenue | $624,569 | — | — | — | — | — | — |
| Sales force revenue | $278,165 | $456,056 | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for AVTX.
Open AVTX in InvestinglyQuestions
Where does Avalo Therapeutics make its money?
In fiscal 2023, by product: Product revenue, net $1M, License and other revenue $516,000.
From Avalo Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.